Celine Boucard
Overview
Explore the profile of Celine Boucard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harlay V, Bertucci A, Boucard C, Petrirena G, Campello C, Barrie M, et al.
Anticancer Res
. 2024 Sep;
44(10):4427-4433.
PMID: 39348991
Background/aim: Treatment of primary central nervous system lymphoma (PCNSL) includes high dose methotrexate-based polychemotherapy (HD-MTX). This study aimed to identify early predictive factors of methotrexate (MTX) delayed elimination. Patients And...
2.
Souberan A, Jiguet-Jiglaire C, Toutain S, Morando P, Baeza-Kallee N, Appay R, et al.
Neuro Oncol
. 2024 Sep;
27(2):415-429.
PMID: 39252580
Background: The generation of patient avatars is critically needed in neuro-oncology for treatment prediction and preclinical therapeutic development. Our objective was to develop a fast, reproducible, low-cost, and easy-to-use method...
3.
Bertucci A, Boucard C, Harlay V, Appay R, Petrirena G, Barrie M, et al.
J Neurol Sci
. 2023 Dec;
457:122847.
PMID: 38129260
No abstract available.
4.
Spinelli M, Boucard C, Ornaghi S, Schoeberlein A, Irene K, Coman D, et al.
JCI Insight
. 2021 Oct;
6(20).
PMID: 34676826
Failed or altered gliogenesis is a major characteristic of diffuse white matter injury in survivors of premature birth. The developmentally regulated long noncoding RNA (lncRNA) H19 inhibits S-adenosylhomocysteine hydrolase (SAHH)...
5.
Spinelli M, Boucard C, Di Nicuolo F, Haesler V, Castellani R, Pontecorvi A, et al.
PLoS One
. 2020 Jun;
15(6):e0232493.
PMID: 32511256
Preterm birth (PTB) is the leading cause of neonatal morbidity and mortality and spontaneous PTB is a major contributor. The preceding inflammation/infection contributes not only to spontaneous PTB but is...
6.
Eggenberger S, Boucard C, Schoeberlein A, Guzman R, Limacher A, Surbek D, et al.
World J Stem Cells
. 2019 Nov;
11(10):891-903.
PMID: 31692977
Background: Perinatal complications may result in life-long morbidities, among which cerebral palsy (CP) is the most severe motor disability. Once developed, CP is a non-progressive disease with a prevalence of...
7.
Autran D, Barrie M, Matta M, Monserrat C, Campello C, Petrirena G, et al.
Anticancer Res
. 2019 Feb;
39(2):1035-1041.
PMID: 30711992
Background/aim: Secondary leptomeningeal gliomatosis (LG) is a rare and severe progression pattern of glioma. Our objective was to evaluate the characteristics and outcome of patients with LG. Patients And Methods:...
8.
Boucard C, Bruschi L, Mandralis K, Seppey C, Staub A
Rev Med Suisse
. 2017 Jul;
12(533):1679-1680.
PMID: 28686384
No abstract available.
9.
Farina P, Tabouret E, Lehmann P, Barrie M, Petrirena G, Campello C, et al.
J Neurooncol
. 2017 Mar;
132(3):433-437.
PMID: 28265824
Matrix metalloproteases MMP2 and MMP9 are involved in cancer angiogenesis and invasion. We recently demonstrated that plasma MMP2 and MMP9 levels could both predict response to bevacizumab in patients with...
10.
Tabouret E, Denicolai E, Delfino C, Graillon T, Boucard C, Nanni I, et al.
J Neurooncol
. 2016 Aug;
130(3):431-437.
PMID: 27566180
Angiogenesis is one of the key features of glioblastoma (GB). However, the use of anti-angiogenic therapies directed against vascular endothelial growth factor (VEGF) is limited by primary or acquired resistance....